Ataraxis AI Unveils $4M-Funded AI Diagnostic Test for Cancer
Slice of Healthcare Team
Nov 05, 2024
Key Highlights
- $4M seed funding led by Giant Ventures and Obvious Ventures.
- Ataraxis Breast: the first AI-native prognostic test for breast cancer.
- Kestrel model: Foundation AI model surpassing current pathology standards.
- 30% more accurate than molecular diagnostics, potentially reducing chemotherapy needs.
- Expanded partnerships with top health systems for patient access.
Source: Business Wire
Notable Quotes
“ Building on our advisor Yann LeCun’s pioneering work in modern AI, we are establishing a completely new category of tests that will phase out molecular diagnostics. ”
Jan Witowski, CEO at Ataraxis AI
“ Ataraxis has the potential to revolutionize cancer treatment, pioneering in a new era of AI-driven precision medicine that will elevate patient care and outcomes. ”
Madelene Larsson, Principal at Giant Ventures
“ Jan and his team have developed a transformative approach using multi-modal AI models to help doctors identify treatment options beyond chemotherapy. ”
Rohan Ganesh, Partner at Obvious Ventures
